What is the correct dosing for tPa (Alteplase) according to FDA approval?

The appropriate dosing for tissue plasminogen activator (tPA, or Alteplase) in the context of FDA approval for treating acute ischemic stroke is 0.9 mg/kg, up to a maximum dose of 90 mg. This dosing guideline ensures that the medication is administered safely and effectively to facilitate thrombolysis, which helps restore blood flow by dissolving the blood clot that is obstructing an artery.

The dosing regimen involves giving 10% of the total dose as an intravenous bolus over one minute, followed by the remaining 90% infused over a period of one hour. This method of administration is designed to optimize the therapeutic effects of tPA while minimizing the risk of complications, particularly the risk of bleeding.

The other dosing choices, while they may represent other contexts in which tPA is used, do not align with the established FDA-approved dosing for acute ischemic stroke treatment. It's crucial for healthcare providers to adhere to these guidelines to ensure patient safety and treatment efficacy.